Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
always sold at loss in the offerings and it runs big in coming weeks, trick is load up on dips and wait for it to unfold in coming weeks
Dermata Therapeutics GAAP EPS of -$2.27
May 11, 2023 5:44 PM ETDermata Therapeutics, Inc. (DRMA)By: Gaurav Batavia, SA News Editor
Dermata Therapeutics press release (NASDAQ:DRMA): Q1 GAAP EPS of -$2.27.
As of March 31, 2023, Dermata had $8.8 million in cash and cash equivalents, compared to $6.2 million as of December 31, 2022.
https://seekingalpha.com/news/3970562-dermata-therapeutics-gaap-eps-of-2_27?utm_source=otcmarkets&utm_medium=referral
The gross proceeds to the Company from the registered direct offering and the concurrent private placement were approximately $1.8 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds for general corporate purposes, which includes, without limitation, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to our technologies, licensing activities related to our current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital.
https://finance.yahoo.com/news/dermata-therapeutics-announces-closing-1-200000286.html
A good read, Price should be much higher. In my opinion. Give it a little time.
the sky is falling
this dilution was uncalled for
You hold and wait, you'll mise a good portion of the profit. imo.
Currently, Dermata has a Zacks Rank #3 (Hold).
Some better-ranked stocks for investors interested in the same sector are CRISPR Therapeutics CRSP, Kala Pharmaceuticals KALA and Allogene Therapeutics ALLO, each carrying a Zacks Rank #2 (Buy)
phase 2 topline results hence pop from .98 to 3.93. under 5m marketcap while its peers have large marketcaps, balance sheet looks good, this small offering dont scare me its not the end of world folks, will average down next week
I think this one is a sleeper, When it wakes up this will be a good place to be. phase 3 begins, volume and price should pick up. IMO.
phase 3 trials start in june
those fucking offerings are strange, always sold. at loss. best to hold it out and wait
they claimed the offering to raise 5m 2 months ago was able to fund operations into 2024, guess not.......
phase 3 trials start it pops
hit with fucking offering for 800k
hit with fucking offering for 800k
DRMA: THANKS, Capt. N-S!!!
2.3m OS, topline results for phase 2, phase 3 in june, small offering in march to raise cash to fund operations till 2024
2.3m OS, topline results for phase 2, phase 3 in june, small offering in march to raise cash to fund operations till 2024
2.3m OS dated may 10 via 10q
nice 10q
may churn another week at best, but we will see large volume spikes and large price spikes in weeks ahead-
many biotechs are broke as fuck with those bs offerings, , we are funded till 2024
all its peers did homeruns
many biotechs are broke as fuck with those bs offerings, , we are funded till 2024
all its peers did homeruns
Agreed, Good Post
same sector as KALA btw had a homerun pop
Currently, Dermata has a Zacks Rank #3 (Hold).
Some better-ranked stocks for investors interested in the same sector are CRISPR Therapeutics CRSP, Kala Pharmaceuticals KALA and Allogene Therapeutics ALLO, each carrying a Zacks Rank #2 (Buy) at present
did 1 to 3.93. tried again, this time we will break highs
offering for 5m was done in march to fund operations till 2024
im all about funding operations, topline clinical trials, market caps and Deadline for phase 3 in june
interesting volume on monthly chart
https://www.stockscores.com/charts/charts/?ticker=drma
DRMA 6-Month Chart
https://www.barchart.com/stocks/quotes/DRMA/technical-chart?plot=BAR&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=DRMA&grid=1&height=500&studyheight=100
3-Month Chart
https://www.barchart.com/stocks/quotes/DRMA/technical-chart?plot=BAR&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=DRMA&grid=1&height=500&studyheight=100
1-Month Chart
https://www.barchart.com/stocks/quotes/DRMA/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=DRMA&grid=1&height=500&studyheight=100
Excellent Chart, Early Beginnings of a Reversal Developed
basing well at much higher prices, with phase 3 trials starting in june, wants to break 3.80 one of these days
https://www.stockscores.com/charts/charts/?ticker=drma
basing well at these prices, phase 2 topline results, phase 3 in june
offering was done in march to fund operations until 2024
im not here to day trade it, higher lows. basing well here
sometimes this acts like it's gonna blow then backs off.
Currently, Dermata has a Zacks Rank #3 (Hold).
Some better-ranked stocks for investors interested in the same sector are CRISPR Therapeutics CRSP, Kala Pharmaceuticals KALA and Allogene Therapeutics ALLO, each carrying a Zacks Rank #2 (Buy) at presen
topline results for phase 2 acne, first drug of its kind, phase 3 in june should run it
offering done in march will fund operation until 2024
bot .starter yesterday
red to green, phase 2 top line results going into phase 3 in june. investment not a day trade
starter
HOOK nice one
cash on hand to fund operations till 2024 catalyst in june , in for starter
held gains
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
258
|
Created
|
08/30/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |